Become an ordering provider and offer our tests at your practice.
Register Now
Leverage DNA Methylation for Precision Cardiovascular Medicine
Our blood tests, powered by AI and rooted in epigenetics and genetics, provide actionable insights into heart attack risk and coronary heart disease.
Conventional Testing Can Leave Critical Gaps
< 20%
of heart disease is genetic, the majority is driven by lifestyle and environment
1 in 5
heart attacks are silent, occuring
without warning
30-65%
of suspected ischemia cases reveal no obstructive disease
Interpreting Cardiovascular Disease Biology With Epigenetics and AI
Epigenetics
Epigenetics refers to chemical changes in DNA that reflect an individual's lifestyle or environment. The majority of heart disease risk is acquired from environmental stressors or lifestyle factors, which leave measurable DNA methylation signatures. DNA methylation is a widely studied epigenetic mechanism and can be easily quantified. By analyzing these heart disease-associated signatures, our blood tests uncover molecular signals tied to disease presence and risk.
Artificial Intelligence
Our solutions integrate artificial intelligence to interpret complex biological data with precision. Proprietary AI models, trained and validated on independent datasets, detect both hidden and overt disease-associated patterns. This AI-driven approach allows multi-dimensional data, including genetic variation and epigenetic markers, to be translated into clinically actionable insights without losing predictive power. This provides a more comprehensive and individualized understanding of coronary heart disease.
Coronary Heart Disease is a Continuum
From Risk Stratification to Disease Management
Quantify Heart Attack Risk with Epi+Gen CHD™
Conventional risk assessments rely on proxy markers such as blood pressure and cholesterol. While these factors may be indicators of heart attack risk, relying on them alone may not be enough. Epi+Gen CHD™ goes deeper, leveraging each patient's unique molecular biology to assess the three-year risk of a coronary heart disease event regardless of the presence or severity of risk factors.
Risk Stratification
Epi+Gen CHD™ quantifies a patient's three-year risk of coronary heart disease event, including heart attack. Risk is classified as low, borderline, intermediate, or high, and benchmarked against peers of the same sex and similar age.
This clinical blood test is recommended for adults aged 35 to 75 year old, who have not been diagnosed with coronary heart disease, suffered a heart attack, undergone cardiac surgery, has not experienced angina or received a bone marrow transplant.
2x
more sensitive than conventional
risk calculators
Non-Invasive, No Radiation, No Fasting
Detect Coronary Heart Disease with PrecisionCHD™
Traditional diagnostic methods can fail to identify coronary heart disease in the early stages and lack insight into patient-specific disease drivers. Research has shown that these tests can miss disease in 20-30% of patients, leading to false negatives and delayed treatment. They also frequently overlook Ischemia with No Obstructive Coronary Arteries (INOCA), where patients may experience chest pain and remain at risk despite the absence of significant plaque buildup. PrecisionCHD™ aids in the diagnosis of coronary heart disease, both obstructive and non-obstructive, and maps each patient’s DNA methylation biomarkers to their disease drivers that could be used to help guide treatment.
Detection and Management
PrecisionCHD™ detects molecular patterns associated with coronary heart disease. An Actionable Clinical Intelligence™ report, included with this test, gives healthcare providers insights into each patient’s specific molecular disease drivers.
PrecisionCHD™ is recommended for adults aged 35 to 80 years old, who are being evaluated for coronary heart disease and have not had a bone marrow transplant.
Test results include actionable insights on the impact of biomarkers on disease signal and associated pathways to help personalize care
Non-Invasive, No Radiation, No Fasting
Ordering a Test for Your Patient is Easy
Test Order
Orders can be submitted online via our Provider Portal or by completing the paper test requisition form included in each sample collection kit.
Test Order
Sample Collection
Sample Collection
Sample collection kits are provided at no cost and include all necessary materials for sample collection and shipping. Practices may choose either vacutainer or lancet-style kits and have the option to ship kits directly to patients' homes.
Test Results
Test Results
Test results will be available in the Provider Portal within 10 business days of sample receipt at our laboratory.
Ready to Offer Precision Cardiovascular Medicine to Your Patients?
Frequently Asked Questions
PrecisionCHD™ was trained on Framingham Heart Study data and validated in collaboration with Intermountain Health and University of Iowa Hospitals and Clinics. The sensitivity is 79% and specificity is 76%.
- Hou K, Burch KS, Majumdar A, et al. Accurate estimation of SNP-heritability from biobank-scale data. Nat Genet. 2019;51(8):1244-1251. doi:10.1038/s41588-019-0465-0
- Heart Disease Facts. CDC. Accessed September 2, 2025. cdc.gov/heart-disease/facts-stats
- Bastiany, A., Pacheco, C., Sedlak, T., Saw, J., Miner, S. E. S., Liu, S., Lavoie, A., Kim, D. H., Gulati, M., & Graham, M. M. (2022). A practical approach to invasive testing in ischemia with no obstructive coronary arteries (INOCA). CJC Open, 4(8), 709-720. https://doi.org/10.1016/j.cjco.2022.04.009
- Dogan MV, Knight S, Dogan TK, Knowlton KU, Philibert R. External validation of integrated genetic-epigenetic biomarkers for predicting incident coronary heart disease. Epigenomics. 2021;13(14):1137-1152. doi:10.2217/epi-2021-0123
- Philibert R, Dogan TK, Knight S, Ahmad F, Lau S, Miles G, Knowlton KU, Dogan MV. Validation of an integrated genetic–epigenetic test for the assessment of coronary heart disease. J Am Heart Assoc. 2023;12:e030934. doi:10.1161/JAHA.123.030934